Page 139 - Merck Sharp News Today

As COVID-19 rages, don’t let your guard down against other viruses May 26, 2021 | 12:02 am THE world’s laser-like focus on SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), hasn’t stopped the medical community from remaining vigilant against other viruses that continue to pose great health risks. One of these is the human papillomavirus (HPV), a sexually transmitted infection that may lead to genital warts and, in worst-case scenarios, cancer. HPV infects at ...

tmrMay 14, 2021 Polypill Products Market: Introduction According to the report, the global polypill products market was valued at US$ 29.7 Bn in 2018 and is projected to expand at a CAGR of ~2% from 2019 to 2027. Polypill is a fixed dose drug combination used in the treatment of various chronic diseases. This combination pharmacotherapy offers the potential to decrease the incidence and prevalence of cardiovascular and other diseases. Polypill improves patient compliance, thereby increasing the...

The Pulmonary Arterial Hypertension Market report at DECISIVE MARKETS INSIGHTS inculcates and provides a detailed synopsis of every aspect of the industry in a detailed manner. The report is a comprehensive study that focuses to provide information on the current market condition and the expected market performance over the forecasted period 2020-2027. The Pulmonary Arterial Hypertension Market report contains insightful data regarding several important aspects such as profit, sales, supply c...

NOXXON Announces Data Safety Monitoring Board Validates NOX-A12 Highest Dose in Phase 1/2 Brain Cancer Trial NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that an independent Data Safety Monitoring Board (DSMB) has confirmed that the highest dose of NOX-A12 in combination with radiotherapy in the ongoing Phase 1/2 study in patients with brain cancer is...

Cocrystal Pharma Announces Closing of $40 Million Bought Deal BOTHELL, Wash., May 07, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, today announced the closing of its previously announced public offering of 26,000,000 shares of co...

10. World Medical Association.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.  11. Desai  RJ, Franklin  JM.  Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.  12. Kimball  A, Hatfield  KM, Arons  M,  et al; Public Health – Seattle & King County; C...

Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021. “Our team is making ...

Marissa Postiglione and Sandy Demuro: Complaint Against Dnarpo Electric, Llc, Domenic Demuro, Sandy Demuro, Justin Postiglione, Marissa Postiglione ( Filing Fee $ 402 Receipt Number 0313-15081290.), Filed By International Brotherhood Of Electrical Workers Local Union No. 98 Profit Sharing Plan, International Brotherhood Of Electrical Workers Local Union No. 98 Pension Plan, International Brotherhood Of Electrical Workers Local Union No. 98 Health & Welfare Fund, International Brotherhood Of El...

May 5, 2021 Therapeutic drug monitoring, half-dosing may not be ready for prime-time Therapeutic drug monitoring (TDM) for patients with immune-mediated inflammatory diseases did not lead to better clinical remission rates, while routine dose reduction of anti-rheumatic drugs for patients with rheumatoid arthritis (RA) in remission offered modest benefits, according to two Norwegian trials. In the NOR-DRUM Part A trial, clinical remission at week 30 was achieved in 50.5% of 198 patients with TD...

Published: May 05, 2021 Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing $723 million as of March 31, 2021 CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 20...